Eli Lilly & Co. (LLY) Tops Q2 EPS by 13c; raises guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $2.11, $0.13 better than the analyst estimate of $1.98. Revenue for the quarter came in at $8.31 billion versus the consensus estimate of $7.58 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2023 EPS of $9.70-$9.90, versus the consensus of $8.71. Eli Lilly & Co. sees FY2023 revenue of $33.4-33.9 billion, versus the consensus of $31.44 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Middleby board approves spin-off of food processing unit Midera
• This digital health stock is ready to re-rate higher: Goldman